erythromycin base filmtab- erythromycin tablet, film coated
physicians total care, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible
erythromycin tablet, film coated
stat rx usa llc - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible
erythromycin capsule, delayed release
stat rx usa - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release capsules and other antibacterial drugs, erythromycin delayed-release capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the er
erythromycin base filmtab- erythromycin tablet, film coated
rebel distributors corp - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin base filmtab tablets and other antibacterial drugs, erythromycin base filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin base filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the ery
erythromycin ethylsuccinate tablet
physicians total care, inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin ethylsuccinate 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susce
erythromycin ethylsuccinate granule, for suspension
wilshire pharmaceuticals inc. - erythromycin ethylsuccinate (unii: 1014ksj86f) (erythromycin - unii:63937kv33d) - erythromycin 200 mg in 5 ml - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate and other antibacterial drugs, erythromycin ethylsuccinate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin ethylsuccinate is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes , streptococcus pneumoniae , or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenza e are not susceptible to the erythromycin concentrati
erythromycin tablet, film coated
arbor pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations
erythromycin capsule, delayed release pellets
mayne pharma inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes, streptococcus pneumoniae, or haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). lower respiratory tract infections of mild to moderate severity caused by streptococcus pneumoniae or streptococcus pyogenes. listeriosis caused by listeria monocytogenes. pertussis (whooping cough) caused by bordetella pertussis. erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible indivi
erythromycin tablet, film coated
pd-rx pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 250 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae ar
erythromycin tablet, film coated
pd-rx pharmaceuticals, inc. - erythromycin (unii: 63937kv33d) (erythromycin - unii:63937kv33d) - erythromycin 500 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets, usp and other antibacterial drugs, erythromycin tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. erythromycin tablets, usp are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes ; streptococcus pneumoniae ; haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of h. influenzae ar